NeoStem Inc (NBS)

NBS

About

NeoStem, Inc. operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices.... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.74
Market Cap (Mil.):	$104.46
Shares Outstanding (Mil.):	193.80
Dividend:	--
Yield (%):	--

Financials

	NBS	Industry	Sector
P/E (TTM):	--	40.13	30.65
EPS (TTM):	-0.37	--	--
ROI:	-57.78	2.36	18.83
ROE:	-72.16	3.58	19.74

Latest News about NBS

» More NBS News

Competitors

	Price	Change
Johnson & Johnson (JNJ.N)	$84.86	-1.50
Sanofi SA (SASY.PA)	€80.79	-0.76
Medtronic, Inc. (MDT.N)	$52.05	-0.87
Baxter International Inc. (BAX.N)	$69.66	-1.22
Harbin Pharmaceutical Group Co., Ltd. (600664.SS)	¥7.10	-0.04
Celgene Corporation (CELG.OQ)	$116.89	-3.35
Shandong Lukang Pharmaceutical Co., Ltd (600789.SS)	¥4.54	-0.09
PerkinElmer, Inc. (PKI.N)	$33.66	-0.75
Shandong Luoxin Pharmacy Stock Co. Ltd (8058.HK)	HK$8.17	-0.12
China Biologic Products Inc (CBPO.OQ)	$23.37	+0.67

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - NEOSTEM, INC. (NBS-A) Provider: Thomson Reuters Stock Report	$25.00 Buy
Wright Investors Service Comprehensive Report for Neostem, Inc. Provider: Wright Reports	$495.00 Buy
NEOSTEM INC (NBS) 12-months forecast Provider: Pechala's Reports	$15.00 Buy
NeoStem Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
ValuEngine Detailed Valuation Report for NBS Provider: ValuEngine, Inc.	$127.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.